Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.

Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F, Tice DA, Pasquale EB.

Cell Signal. 2011 Jan;23(1):201-12. doi: 10.1016/j.cellsig.2010.09.004. Epub 2010 Sep 15.

2.
3.

EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, Sloan AE, Cohen ML, Wang B.

Cancer Cell. 2009 Jul 7;16(1):9-20. doi: 10.1016/j.ccr.2009.04.009.

4.

Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation.

Zhuang G, Hunter S, Hwang Y, Chen J.

J Biol Chem. 2007 Jan 26;282(4):2683-94. Epub 2006 Nov 29.

5.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

6.

Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.

Ståhl S, Branca RM, Efazat G, Ruzzene M, Zhivotovsky B, Lewensohn R, Viktorsson K, Lehtiö J.

J Proteome Res. 2011 May 6;10(5):2566-78. doi: 10.1021/pr200037u. Epub 2011 Apr 11.

PMID:
21413766
7.

Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.

Tawadros T, Brown MD, Hart CA, Clarke NW.

Br J Cancer. 2012 Nov 6;107(10):1737-44. doi: 10.1038/bjc.2012.457. Epub 2012 Oct 4.

8.

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 May 24;12:46. doi: 10.1186/1476-4598-12-46.

9.
11.

Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.

Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N.

BMC Cancer. 2012 Jul 23;12:309. doi: 10.1186/1471-2407-12-309.

12.

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N.

Cancer Discov. 2011 Aug;1(3):248-59. doi: 10.1158/2159-8290.CD-11-0085. Epub 2011 Jun 17.

13.

Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.

Miao H, Burnett E, Kinch M, Simon E, Wang B.

Nat Cell Biol. 2000 Feb;2(2):62-9.

PMID:
10655584
14.

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.

Biosci Rep. 2012 Aug;32(4):413-22. doi: 10.1042/BSR20120050.

15.

Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.

Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB.

J Biol Chem. 2003 Oct 10;278(41):40057-66. Epub 2003 Jul 17.

16.

Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.

Shang X, Lin X, Howell SB.

Cell Commun Signal. 2014 Oct 25;12:59. doi: 10.1186/s12964-014-0059-5.

17.

AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.

Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD, Pearson RB.

Oncogene. 2012 Apr 12;31(15):1949-62. doi: 10.1038/onc.2011.394. Epub 2011 Sep 12.

18.

EphA2/Ephrin-A1 signaling complexes restrict corneal epithelial cell migration.

Kaplan N, Fatima A, Peng H, Bryar PJ, Lavker RM, Getsios S.

Invest Ophthalmol Vis Sci. 2012 Feb 23;53(2):936-45. doi: 10.1167/iovs.11-8685. Print 2012 Feb.

19.
20.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk